Supernus Pharmaceuticals, Inc. (SUPN)
After hours:
| Previous Close | 29.95 |
| Open | 29.96 |
| Bid | 30.24 x 100 |
| Ask | 30.31 x 100 |
| Day's Range | 29.82 - 30.40 |
| 52 Week Range | 21.99 - 38.09 |
| Volume | |
| Avg. Volume | 389,266 |
| Market Cap | 1.656B |
| Beta (5Y Monthly) | 0.99 |
| PE Ratio (TTM) | 1,513.00 |
| EPS (TTM) | 0.02 |
| Earnings Date | May 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.50 |
GlobeNewswireSupernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it expects to report financial and business results for the first quarter of 2024 after the market closes on Wednesday, May 8, 2024. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to p
- GlobeNewswire
Supernus Provides Regulatory Update for SPN-830
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced a regulatory update for SPN-830. SPN-830 is an investigational apomorphine infusion device for the continuous treatment of motor fluctuations (“off” episodes) in Parkinson’s disease (PD) under U.S. Food and Drug Administration (FDA) review. The FD
- GlobeNewswire
Supernus to Participate in Two Upcoming Investor Conferences
ROCKVILLE, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences: Jefferies Biotech on the Bay SummitDate:Tuesday, March 12, 2024Place:The 1 Hotel South Beach, Miami, Fla. Barclays Glob
